Literature DB >> 28421234

The Role of Topical Timolol in the Treatment of Infantile Hemangiomas: A Systematic Review and Meta-analysis.

Maham Khan1, Aaron Boyce, David Prieto-Merino, Åke Svensson, Emma Wedgeworth, Carsten Flohr.   

Abstract

To date the efficacy and safety of topical timolol in the treatment of infantile hemangioma has not been reviewed and analysed systematically. We collated all published data on the efficacy and safety of topical timolol in the treatment of infantile hemangioma. A total of 31 studies with 691 patients were included. The fixed effects pooled estimate of the response rate defined as any improvement from baseline of infantile hemangioma after treatment with topical timolol was significant (RR = 8.96; 95% CI 5.07-15.47; heterogeneity test p = 0.99), and the treatment was overall well tolerated. However, the quality of evidence was low to moderate. Topical timolol is an effective treatment for small infantile hemangioma, with no significant adverse effects noted. However, there is still a need for adequately powered randomised controlled trials.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28421234     DOI: 10.2340/00015555-2681

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  8 in total

Review 1.  Medical Management of Infantile Hemangiomas: An Update.

Authors:  Caroline Colmant; Julie Powell
Journal:  Paediatr Drugs       Date:  2021-10-22       Impact factor: 3.022

2.  Good Clinical Responders to Topical Timolol in Patients with Infantile Hemangiomas: A 7-Year Retrospective Study of 328 Korean Patients.

Authors:  Da-Ae Yu; Se Hee Min; Jaeryong Song; Jong Seo Park; Hanjae Lee; Jungyoon Ohn; Kyu Han Kim
Journal:  Ann Dermatol       Date:  2022-10       Impact factor: 0.722

Review 3.  Update on Treatment of Infantile Hemangiomas: What's New in the Last Five Years?

Authors:  Laura Macca; Domenica Altavilla; Luca Di Bartolomeo; Natasha Irrera; Francesco Borgia; Federica Li Pomi; Federico Vaccaro; Violetta Squadrito; Francesco Squadrito; Mario Vaccaro
Journal:  Front Pharmacol       Date:  2022-05-26       Impact factor: 5.988

4.  LncRNA OIP5-AS1 Promotes the Proliferation of Hemangioma Vascular Endothelial Cells via Regulating miR-195-5p/NOB1 Axis.

Authors:  Jiayu Zhang; Tiancheng Zhao; Leilei Tian; Yezhou Li
Journal:  Front Pharmacol       Date:  2019-04-24       Impact factor: 5.810

5.  Application of the adenosine triphosphate sensitivity assay in infantile vascular anomalies.

Authors:  Li Li; Bin Yang; Li Wei; Bin Zhang; Xiao-Feng Han; Zi-Gang Xu; Lin Ma
Journal:  BMC Pediatr       Date:  2020-02-19       Impact factor: 2.125

6.  Evaluation of Transdermal Transport and Concurrent Cutaneous Hydrolysis of Timolol Prodrug for the Treatment of Infantile Hemangiomas.

Authors:  Shih-Jen Chang; Huiyuan Wang; Jialin Chen; Qianyi Chen; Lei Chang; Yongzhuo Huang; Yajing Qiu; Xiaoxi Lin
Journal:  Pharmaceutics       Date:  2022-08-01       Impact factor: 6.525

7.  Effect of combined low-dose oral prednisone with beta-adrenergic receptor antagonists for refractory infantile hemangiomas: retrospective cohort study in 76 patients.

Authors:  Chao Liu; Ze-Liang Zhao; Hai-Wei Wu; Jia-Wei Zheng; Yan-An Wang; Xue-Jian Liu; Xin-Dong Fan
Journal:  Ann Transl Med       Date:  2019-12

8.  Management of infantile hemangiomas during the COVID pandemic.

Authors:  Ilona J Frieden; Katherine B Püttgen; Beth A Drolet; Maria C Garzon; Sarah L Chamlin; Elena Pope; Anthony J Mancini; Christine T Lauren; Erin F Mathes; Dawn H Siegel; Deepti Gupta; Anita N Haggstrom; Megha M Tollefson; Eulalia Baselga; Kimberly D Morel; Sonal D Shah; Kristen E Holland; Denise M Adams; Kimberly A Horii; Brandon D Newell; Julie Powell; Catherine C McCuaig; Amy J Nopper; Denise W Metry; Sheilagh Maguiness
Journal:  Pediatr Dermatol       Date:  2020-05-16       Impact factor: 1.997

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.